Cost Curve
Posts
MFN 'Conversations' Have Started, Pfizer’s Bourla Says, But There’s Not Much There There

MFN 'Conversations' Have Started, Pfizer’s Bourla Says, But There’s Not Much There There

And Sandoz’s web page for its new biosimilar, Jubbonti, has a “value” section that breaks new ground

Jun 10, 2025

Subscribe to Cost Curve Apex to read the rest.

Upgrade to Apex to get access to this post and other subscriber-only content.

No posts found